Researchers explore the impact of CD163-positive tumor-associated macrophages on the effectiveness of nivolumab in treating ...

Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a ...

Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion-mutated NSCLC, ...

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover ...

During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte ...

Hardeep Phull, MD, director of oncology at Palomar Health, discusses the value of virtual health care and telehealth for both ...

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent ...

During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ...

Neoadjuvant darovasertib elicited strong antitumor activity, reduced simulated radiation doses, and lowered the risk of ...

Promising results emerge from a clinical trial combining IDE397 and Trodelvy for treating MTAP-deleted urothelial cancer, ...

Joseph Jacob, MD, discusses gemcitabine intravesical delivery as a highly effective treatment for high-risk, BCG-unresponsive bladder cancer, achieving an 82% response rate.

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in ...